369 related articles for article (PubMed ID: 24747236)
1. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy.
Sinha V; Zhao P; Huang SM; Zineh I
Clin Pharmacol Ther; 2014 May; 95(5):478-80. PubMed ID: 24747236
[TBL] [Abstract][Full Text] [Related]
2. "Getting the dose right": facts, a blueprint, and encouragements.
Peck CC; Cross JT
Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
[No Abstract] [Full Text] [Related]
3. Physiologically-based pharmacokinetics in drug development and regulatory science.
Rowland M; Peck C; Tucker G
Annu Rev Pharmacol Toxicol; 2011; 51():45-73. PubMed ID: 20854171
[TBL] [Abstract][Full Text] [Related]
4. Microdosing Studies in Children: A US Regulatory Perspective.
Roth-Cline M; Nelson RM
Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
[TBL] [Abstract][Full Text] [Related]
5. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
Nakashima K; Narukawa M; Takeuchi M
Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
[TBL] [Abstract][Full Text] [Related]
6. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
[TBL] [Abstract][Full Text] [Related]
7. Why Collecting Pharmacokinetic Information After Intravenous Drug Administration Is Important.
Hinderling PH; Papoian T
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):146-150. PubMed ID: 31943891
[No Abstract] [Full Text] [Related]
8. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians.
de Leon J; Spina E; Diaz FJ
J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070
[No Abstract] [Full Text] [Related]
9. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
Milton MN; Horvath CJ
Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
[No Abstract] [Full Text] [Related]
10. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
11. Sources of variability in clinical trials of new drugs for epilepsy.
Leppik IE
Epilepsy Res Suppl; 1993; 10():157-66. PubMed ID: 8251091
[No Abstract] [Full Text] [Related]
12. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
Browne TR
Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
[No Abstract] [Full Text] [Related]
13. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.
Leong R; Vieira ML; Zhao P; Mulugeta Y; Lee CS; Huang SM; Burckart GJ
Clin Pharmacol Ther; 2012 May; 91(5):926-31. PubMed ID: 22472993
[TBL] [Abstract][Full Text] [Related]
14. Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.
Zhang Y; Wang Y; Khurana M; Sachs HC; Zhu H; Burckart GJ; Alexander J; Yao LP; Wang J
Clin Pharmacol Ther; 2020 Jul; 108(1):90-98. PubMed ID: 32030741
[TBL] [Abstract][Full Text] [Related]
15. Assessment of factors associated with dose differences between Japan and the United States.
Arnold FL; Fukunaga S; Kusama M; Matsuki N; Ono S
Clin Pharmacol Ther; 2014 May; 95(5):542-9. PubMed ID: 24281222
[TBL] [Abstract][Full Text] [Related]
16. The use of the noninferiority analysis in clinical studies.
Bermingham EC; del Castillo JR; Radecki SV
Equine Vet J; 2014 Jul; 46(4):399-401. PubMed ID: 24909652
[No Abstract] [Full Text] [Related]
17. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
18. Modeling and simulation of biopharmaceutical performance.
Zhang X; Lionberger RA
Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
[TBL] [Abstract][Full Text] [Related]
19. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.
Bhattaram VA; Bonapace C; Chilukuri DM; Duan JZ; Garnett C; Gobburu JV; Jang SH; Kenna L; Lesko LJ; Madabushi R; Men Y; Powell JR; Qiu W; Ramchandani RP; Tornoe CW; Wang Y; Zheng JJ
Clin Pharmacol Ther; 2007 Feb; 81(2):213-21. PubMed ID: 17259946
[TBL] [Abstract][Full Text] [Related]
20. The domestic drug regulatory process: why time is of the essence.
Katz R
Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
